Literature DB >> 15022318

Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus.

Shih-Chang Lin1, Jeng-Hsien Yen, Jaw-Ji Tsai, Wen-Chen Tsai, Tsan-Teng Ou, Hong-Wen Liu, Chung-Jen Chen.   

Abstract

OBJECTIVE: The expression of autoimmunity in mice deficient in programmed death 1 (PD-1) suggests that PD-1 is a candidate gene involved in the development of human autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We therefore tested the potential association between PD-1 and the development of SLE and RA by conducting case-control genetic-association studies.
METHODS: Ninety-eight SLE patients, 84 RA patients, and sex-matched control subjects for each disease group were recruited and genotyped for a single-nucleotide polymorphism, C+872T, in the human PD-1 gene. The significance of the association of the PD-1 gene with SLE or with RA was analyzed by statistical tests for the difference in genotype distribution between disease and control groups.
RESULTS: The human PD-1 gene was found to be significantly associated with disease development in RA patients, but not SLE patients. The risk of RA development appeared to be significantly increased by carriage of the T allele (odds ratio 3.32, P < 0.0001) or the C/T genotype (odds ratio 3.52, P < 0.00005).
CONCLUSION: The PD-1 gene is significantly associated with RA susceptibility, suggesting the possibility that PD-1 may contribute to the pathogenesis of RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022318     DOI: 10.1002/art.20040

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  52 in total

1.  Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men.

Authors:  Mohammad Reza Zamani; Firouzeh Akbari Asbagh; Amir Hossein Massoud; Arash Salmaninejad; Ahmad Massoud; Nima Rezaei
Journal:  J Assist Reprod Genet       Date:  2014-11-16       Impact factor: 3.412

Review 2.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

3.  Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis.

Authors:  Paula S Ramos; Elisabeth E Brown; Robert P Kimberly; Carl D Langefeld
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

4.  [How do T-cells become activated in joints?].

Authors:  M Pierer; U Wagner
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

5.  The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium.

Authors:  Guoning Guo; Yongjun Shang; Guoyan Zhu; Xiaoren Bao; Shiwei Xu; Yongwen Chen
Journal:  Clin Rheumatol       Date:  2011-07-22       Impact factor: 2.980

Review 6.  The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility.

Authors:  Marta E Alarcón-Riquelme
Journal:  Springer Semin Immunopathol       Date:  2006-09-09

7.  The programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with non-small cell lung cancer risk in a Chinese Han population.

Authors:  Liu Yin; Huishu Guo; Lei Zhao; Jinguang Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

8.  PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children.

Authors:  Ronghua Ni; Kenji Ihara; Kenichi Miyako; Ryuichi Kuromaru; Mika Inuo; Hitoshi Kohno; Toshiro Hara
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

9.  Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population.

Authors:  Xiang Liu; Li-Hua Hu; Yi-Rong Li; Feng-Hua Chen; Yong Ning; Qun-Feng Yao
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

10.  Program Death-1 Suppresses Autoimmune Arthritis by Inhibiting Th17 Response.

Authors:  Lifen Yang; Guilin Qiao; Yassir Hassan; Zhenping Li; Xiaoqing Zhang; Huimin Kong; Weimin Zeng; Fei Yin; Jian Zhang
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-19       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.